In the central control room, a large screen of 3 people high is constantly flashing. On the screen, along with the changes in the operation data of each process of the production line, the number of bags grabbed by the intelligent robot in the workshop, the number of bags pushed into the boxes by the cartoning machine, and the number of boxes sealed into the warehouse by the cartoning machine are automatically recorded.

On October 25, in the granule production workshop of Liaoning China Resources Benxi Three Pharmaceuticals Co., Ltd, workshop director Zhang Lijun just returned from the big screen in the central control room. "The numbers on the screen also show the drug process parameters, including moisture, strength, content and so on." Zhang Lijun said, "The inlet air pressure and inlet air temperature of the workshop will make the process parameters fluctuate, and I am monitoring the technology according to the numbers on the screen."

"Previously, grabbing the bags and pushing them into the boxes were manual operations, which were not only time-consuming but also very costly." Zhang Lijun said, "In recent years, the company has achieved artificially intelligent production of key processes, which has not only shortened the production cycle, but also improved production efficiency, and the output value of its main products, Inibu Capsules and Blood Stasis Paralysis Tablets, have both increased by more than 20%." With the boxes of packed drugs starting to be loaded, Zhang Lijun once again returned to the large screen in the central control room, where he had to proofread the process parameters of the drugs again before shipping.

In recent years, in order to promote the cultivation of large varieties of traditional Chinese medicine and brand enhancement, Benxi Sanyo has invested 400 million yuan in technological transformation, integrating the concept of "products from design, high standards, high starting point, green and environmental protection" into the production line technology improvement project.

"Modern Chinese medicine manufacturers need to take process quality as the core, realize the transformation from rough production to lean production, and comprehensively improve the technological content and clinical value of products." Shi Yong, director of the Intelligent Manufacturing Office, said. Under the research and development of Shi Yong and his team, SanPharma has adopted PAT and PKS technologies to build a multi-dimensional data heterogeneous integration and statistical analysis, realizing interconnection of facilities, interoperability of systems, mutual sharing of data, and inter-integration of business models in an intelligent control system.

At present, China Resources Benxi Sanyo's granule automatic packaging line with an investment of RMB 21.63 million is setting a new height for Chinese medicine manufacturing. Through the implementation of intelligent manufacturing informatization project and AI key technology research for large varieties of granules, it is creating a new model of high quality, low cost and fast delivery for TCM manufacturing and creating new competitive points for marketing.

As of September, Benxi Sanyo achieved operating revenue of RMB 420.23 million, up 13% year-on-year, and profit and tax of RMB 81.28 million, up 10% year-on-year. The company is moving from traditional Chinese medicine manufacturing to Chinese medicine "smart" manufacturing through intelligent transformation.